Outcomes of the Monoconversion to Valproate or Lamotrigine for Absence Seizures.
- Author:
Joong Hyun BIN
1
;
Sun Young PARK
;
Ji Yoon HAN
;
Tae Hoon EOM
;
Seong Joon KIM
;
Young Hoon KIM
;
In Goo LEE
;
Seung Yun CHUNG
Author Information
1. Department of Pediatrics, College of Medicine, Catholic University of Korea, Seoul, Korea. sycped@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
Epilepsy;
Absence;
Ethosuximide;
Child
- MeSH:
Anticonvulsants;
Child;
Electroencephalography;
Epilepsy;
Epilepsy, Absence*;
Ethosuximide;
Freedom;
Humans;
Korea;
Retrospective Studies;
Seizures;
Valproic Acid*
- From:
Journal of the Korean Child Neurology Society
2014;22(2):69-71
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Ethosuximide (ESX) is currently not available due to various reasons in Korea. The aim of this study is to compare the efficacy of valproate (VPA) and lamotrigine (LTG) when ESX monotherapy was replaced by VPA or LTG. METHODS: A retrospective study was done for a total of 34 patients treated with ESX in 5 different hospitals affiliated with Catholic University of Korea from January, 2010 to December, 2012. They all were initially treated with ESX, but later switched to VPA or LTG. The subjects were selected based on clinical symptoms and electroencephalography findings. RESULTS: Among 34 patients, VPA was prescribed to 17 patients (50.0%) and LTG to 17 patients (50.0%). Twenty patients (58.8%) achieved the seizure freedom after 3 months of the treatments, 13 patients (76.5%) by VPA and 7 (41.2%) by LTG respectively. Four patients (23.5%) with VPA and 10 (58.8%) with LTG were replaced by other anticonvulsants due to ineffectiveness and/or side effects of medication. When we compare the efficacy of seizure reduction between VPA and LTG after 3 month period of the treatment, the efficacy of VPA was better than that of LTG (P=0.04). CONCLUSION: The results of this study suggest that the VPA is a better alternative anticonvulsant than LTG for the patients with absence epilepsy who are unable to continue ESX.
